Ligand Pharmaceuticals Incorporated - Investor Relations
Mar 25, 2026 · Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value …
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 26, 2026 · Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “We delivered strong fourth …
Ligand and Medtronic Commit $70 Million in Strategic Capital to ...
Jul 31, 2025 · Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB, plus $5 million in an equity private placement Medtronic to invest $10 …
Ligand Reports First Quarter 2025 Financial Results
May 8, 2025 · First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel …
Ligand Pharmaceuticals Incorporated - Stock Info
Apr 17, 2026 · All 3m NASDAQ:LGND News Releases Jan 26 Feb 2 Feb 9 Feb 16 Feb 23 Mar 2 Mar 9 Mar 16 Mar 23 Mar 30 Apr 6 Apr 13 Apr 20 2021 2022 2023 2024 2025 2026 160 180 200 220 ...
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Nov 6, 2025 · The trademarks Ligand owns include Ligand, Captisol, NITRICIL and Zelsuvmi. Solely for convenience, some of the trademarks and copyrights referred to in this press release are listed …
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has …
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel …
Apr 17, 2025 · About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this …
Ligand to Participate in March Investor Conferences
JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming …
Ligand Advances Strategic Growth with Expanded and Strengthened ...
Mar 26, 2026 · Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. The company’s royalty portfolio is designed to deliver …